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Background: In this manuscript, we argue that within the context of phase IV, physician-researchers retain their
fiduciary obligation to treat the patient-participants.
Discussion: We first clarify why the perspective that research ethics ought to be differentiated from clinical ethics is
not applicable in phase IV, and therefore, why therapeutic orientation is most convivial in this phase. Next,
assuming that ethics guidelines may be representative of common morality, we show that ethics guidelines see
physician-researchers primarily as physicians and only secondarily as researchers. We then elaborate on what a
fiduciary obligation is and how some of the obligations are default duties. Lastly, we look at the fiduciary obligation
of the physician-researcher in phase IV interventional trials.
Conclusion: The fiduciary obligation to treat is not as easily waived as in earlier trials. Assuming the entwinement
of research and practice in phase IV, physician-researchers, in collaboration with other researchers, investigators, and
research ethics committees, should ensure that in terms of study design, methodology, and research practice, the
therapeutic value of the research to the patient-participants is not diminished.
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A more rigorous and scientifically robust phase IV within
the drug development system [1] is important both for the
continuous appraisal of the benefit-risk profile of a drug
and for the evaluation of the drug’s economic value (for
reimbursement purposes, for example). In the case of the
former, the continuous appraisal of a drug’s benefit-risk
profile is highlighted by the present drive towards a
shorter but more efficient pre-authorization drug develop-
ment phase [2,3] and the concomitant move towards pro-
gressive authorization, that is, authorization that allows
earlier but limited release of a drug and license expansion
is dependent on new data [4]. On top of that, there is in-
creased attention on phase IV studies required by the
FDA due to safety signs that may affect the benefit-risk
profile of a drug [5,6].
By phase IV, we refer to “all studies (other than routine
surveillance) performed after drug approval and related to
the approved indication” such as “drug-drug interaction* Correspondence: R.Bernabe@umcutrecht.nl
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reproduction in any medium, provided the orstudies, dose–response or safety studies and studies de-
signed to support use under the approved indication” [7]
as well as studies to obtain health economic data. These
studies are usually “larger, less technically complicated
than pre-registration studies, have fewer inclusion/exclu-
sion criteria and are more likely to include subjective or
qualitative end points” [8]. Also, these studies are meant
to gather real-world data for the purpose of informing
clinical decisions [9,10]. As such, many or most phase IV
studies occur within the doctor’s clinic.
Granted the fact that not all safety and efficacy issues
are known at the time of approval, it is also a given fact
that upon authorization, drugs are declared to have
proven safety, efficacy, and quality, and as such, it is rea-
sonable for patients and medical practitioners to have
expectations of benefit from these drugs. In a phase IV
study, therapy and research are necessarily intertwined
due to the tension between the reasonable expectation
of benefit and the knowledge gaps in drug safety and ef-
ficacy. Social policies such as coverage with evidence de-
velopment assume this entwinement by making access
to therapy dependent on research participation. This en-
twinement is highlighted by the fact that these studiesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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researcher conflict is especially perceived in phase IV.
In this paper, we shall argue that since phase IV trials
are by nature and purpose closer to practice than the
other phases of drug development, physician-researchers
are primarily physicians and secondarily researchers
whose fiduciary obligation to their patient-participants
remains, although some aspects of this obligation may be
waived. When we speak of physicians, we refer specific-
ally and narrowly to treating physicians and not to car-
eer researchers who happen to have a medical degree.
By career researchers, we refer to those who do not have
patients themselves; rather, they are full-fledged re-
searchers who might be working for CROs or pharma-
ceutical companies. Further, we shall limit ourselves to
phase IV trials that are interventional, i.e., trials where
the therapy that the patient-participant receives is dic-
tated by the protocol; the physician’s prescription is re-
lated to the patient-participant’s inclusion in the trial;
and additional diagnostic or monitoring procedures are
necessary [11].
To achieve our aim, we shall first show that physician-
researchers are primary physicians and secondarily re-
searchers by looking at relevant ethics guidelines. Next,
we shall discuss what the latter means by situating our
discussion within that of fiduciary obligation. Within this
discussion of fiduciary obligation, it is necessary to
briefly take a step back and show that the physician-
patient relationship is fiduciary in nature, and that some
aspects of this obligation may be waived for the purpose
of research. Lastly, we revisit phase IV and demonstrate
the implications of our main thesis.
The conflict: phase IV research and therapeutic obligation
Two approaches to clinical research ethics dilemmas
Dilemmas in clinical research ethics are usually approached
by either A.) stating that research and practice are different
and hence the ethical requirements of research ought to be
differentiated from the requirements of practice; or, B.) by
viewing research as essentially related to practice. These
two approaches are best represented by the discussion in
the literature on therapeutic orientation [12-16]. By thera-
peutic orientation, we refer to the inclination or the mind-
set where research is seen in terms of therapeutic morality
[12], i.e., the mindset that does not fully separate or fully
distinguish the following:
…“practice” refers to interventions that are designed
solely to enhance the well-being of an individual
patient or client and that have a reasonable expectation
of success…. By contrast, the term “research” designates
an activity designed to test a hypothesis, permit
conclusions to be drawn, and thereby to develop or
contribute to generalizable knowledge… [17].F. Miller and Rosenstein [12] and Appelbaum and Lidz
[18] may be representative of perspective A on the
practice-research distinction. For them, the difference be-
tween research and practice in terms of aims and relation-
ships is ethically significant: research aims to “produce
generalizable knowledge” while practice aims to “provide
individual patients with optimal care”. Hence, therapeutic
orientation ought to be seen as a problem that must be
solved in research ethics. On the other hand, Anderson
[19], Freedman [20], Comoretto [15], and Lemmens and
P. Miller [21] are some examples of thinkers who repre-
sent perspective B. For Anderson, for example, research
and practice are epistemologically linked since practice
provides methodological constraints to research [19]. In
terms of therapeutic orientation, removing it from re-
search is an approach [21] that unnaturally separates re-
search from its goal, i.e., therapeutic benefit.
Depending on which perspective we take, we can pro-
vide different responses to our main question. In this
paper, we relate more to perspective B and we shall do so
by putting this therapeutic orientation within the discus-
sion of the fiduciary obligation of physician-researchers.
But before we explicate our point, some words are in
order on the entwinement of research and practice in
phase IV.
Why perspective A is not applicable to the physician-
researcher dilemma in phase IV
Phase IV is a peculiar phase among the other phases of
drug development precisely because of the marketing
authorization of the drug being studied within this
phase. Thus, unlike earlier phases, a comparative phase
IV trial refers to the comparison of two authorized
drugs. Authorization means that it is logical to expect a
two-armed trial between a trial drug and a non-placebo
comparator to have reasonable levels of safety and ef-
fectiveness. This is a noteworthy difference between
phase IV and the other phases where safety and efficacy
cannot yet be reasonably expecteda. This means that to a
certain extent, any phase IV trial that excludes a placebo
arm is naturally and essentially therapeutic.
A phase IV interventional study is therapeutic not only
because, in the absence of placebo, the drugs involved
are licensed drugs; as mentioned above, the purpose of
such trials is to inform clinical decisions. In an earlier
study, we have elaborated on informing a decision as
follows:
…a phase IV trial should aim at “informing a clinical
decision.” We defined “informing a decision” to refer
to clinically relevant differences that would allow
physicians to reasonably choose one drug over
another… However, these clinically relevant differences
also matter in the decision-making processes of the
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groups, pharmaceutical industry, and third party payers.
The importance of these clinically relevant differences
is illustrated by the emergence of relative effectiveness
as an important issue in the post-authorization stage…
Ultimately, the aim of relative effectiveness assessment
is “to compare healthcare interventions in practice in
order to classify them according to their practical
therapeutic value” [9].
Thus, a phase IV study basically aims to effectively and
positively affect clinical decision-making by gathering
real-life data as much as possible
As a consequence of the therapeutic nature of phase
IV whose goal is to gather (real-life) data that informs
clinical decisions, the common setting for these usually
large and less technically complicated trials is the physi-
cian’s clinic. We wish to note that though earlier phases
are done in clinics/hospitals as well, there is still a differ-
ence: earlier phases are done in clinics because these are
convenient research centers where necessary medical
tests and procedures may be done. Phase IV trials, on
the other hand, are done in clinics precisely because these
trials are meant to gather data about a drug once it is sent
out to the world. Simply, phase IV trials are intimate with
practice, i.e., therapy is not just a “common effect” of a
phase IV interventional study; rather, it ought to be a ne-
cessary consideration in its design and execution.
Since by nature and purpose phase IV trials are closer
to practice than the other phases, perspective A, which
demands two separate ethics for research and practice, is
simply not applicable for this phase. In phase IV, re-
search and practice are intertwined. In what follows, we
shall discuss that physician-researchers are primarily
physicians and only secondarily researchers; after which,
we shall elaborate on what this means by putting this
discussion within the context of fiduciary obligation.
Physician-researchers are primarily physicians
Physician-researchers are primarily physicians who are
engaged in research; they are not dissociative identity
professionals who struggle between being fully a phys-
ician and being fully a researcher. By looking at some
medical ethics guidelines for physicians, we get a better
grasp of this. Admittedly, we are not arguing for this
point; rather, we are demonstrating that based on the
ethics codes of some medical associations, it is the pre-
dominant perception that physician-researchers are pri-
marily physicians who are doing research.
The 2013 Helsinki Declaration is unambiguous in
terms of the priorities of physicians involved in research
(refer to Table 1). Since the Helsinki Declaration is a
document that was ratified with the participation of
delegates from its constituent member countries, andorganizations such as the International Conference on Har-
monisation [22] and the European Medicines Agency [23]
have since acknowledged the authority of this declaration
without issuing any divergence or disagreement with it, the
moral ascendancy of this declaration over its constituent
member countries is almost without question. This is the
closest we can get to common morality in the absence of a
survey of all the existing national codes of ethics.
In agreement with and as a support to what is stated
in the Helsinki Declaration, the Australian Medical
Association’s and the UK General Medical Council’s
codes of medical ethics provide explicit and straightfor-
ward statements on physicians’ priorities when involved in
research (refer to Table 1). We wish to note that since we
have not done an exhaustive comparison of the various
national codes of medical ethics, it is possible that some
national codes of medical ethics would disagree with those
of the UK and Australia or even with Helsinki. However,
since we assume the primacy of Helsinki, and since we
used the UK and Australian codes as auxiliaries, we be-
lieve our stance will not be substantially affected by a po-
tential disagreement between national codes.
Hence, it seems at the very least agreed upon by the
international medical community (and the medical com-
munities of the two countries concerned) that these are
codes of ethics for physicians who may be doing research.
Hence, physician-researchers are not individuals with
two contrasting and separate hats: that of the physician
and that of the researcher. Rather, they are physicians
who must follow certain guidelines when involved in re-
search. Second, these ethics codes explicitly state that in
the event that a physician engages herself/himself in re-
search, the priority is clear: the well-being/health/rights/
interest/protection of the patient-participant. Granted
that there may be variations on how to interpret words
like “well-being” or “interest”, it is still without doubt
that these various codes require the physician to put the
patient first over research interests.
The fiduciary obligation of physicians and the possibility
of waiver
In the succeeding sections, our ultimate aim is to pro-
vide clarification of what it means for physicians, as fidu-
ciaries, to put the patient-participant first within the
context of phase IV. However, before proceeding, we
need to take a few steps back: first, it is necessary to dis-
cuss what we mean by a fiduciary relationship; second,
describe the physician-patient relationship as a fiduciary
relationship; and third, discuss the possibilities of waiver
of the fiduciary obligation for purposes of research.
Fiduciary relationships
A fiduciary relationship is a service relationship that is
meant for the provision of a service that public policy
Table 1 Ethical codes of some medical associations that state what the priority is of the physician-researcher when
doing research
Medical association Statement in the medical ethics guideline on physician priority in research
World Medical Association [24] Declaration of Helsinki:
3. The Declaration of Geneva of the WMA binds the physician with the words,
“The health of my patient will be my first consideration,” and the International
Code of Medical Ethics declares that, “A physician shall act in the patient’s
best interest when providing medical care.”
4. It is the duty of the physician to promote and safeguard the health,
well-being and rights of patients, including those who are involved in
medical research. The physician’s knowledge and conscience are
dedicated to the fulfilment of this duty.
8. While the primary purpose of medical research is to generate new
knowledge, this goal can never take precedence over the rights and
interests of individual research subjects.
Australian Medical Association [25] AMA Code of Ethics:
1.2 Clinical Research
c. Recognise that considerations relating to the well-being of individual
participants in research take precedence over the interests of science or society.
UK General Medical Council [26] Good Medical Practice (Research):
71. If you are involved in designing, organising or carrying out research, you must:
a. put the protection of the participants’ interests first
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more persons are involved: the fiduciary, the entrustor,
and in some instances, the beneficiary who may be
distinct from the entrustor such as the case of
trustors-trustees-beneficiaries. Relationships such as
the following are considered fiduciary: solicitor-client,
director-corporation, trustee-trustor, and of course,
physician-patient [27,28]. A fiduciary relationship is dis-
tinct from a contractual relationship due to the power im-
balance between the fiduciary and the entrustor. In a
contract relation, the two contracting parties are consid-
ered as independent; in a fiduciary relationship, the fidu-
ciary is entrusted with power to enable her/him to provide
a specific service to the entrustor. Precisely because of this
power and the service that the fiduciary provides through
this power, the entrustor is to a certain extent necessarily
dependent on the fiduciary [29].
Traditionally, the duties of the fiduciary may be cate-
gorized into two: duty of loyalty and duty of care. The
duty of loyalty refers to the broad category of preventa-
tive duties that protect the entrustor’s right to honesty,
and hence, the prevention of the fiduciary from using
power without authorization [27]. To uphold this broad
duty, fiduciaries may be required, for example, to ac-
count for entrusted assets, to not compete with the
entrustor within the service area concerned, and not to
create situations in which the fiduciary may have a con-
flict of interest that may compromise the entrustor [27].
The duty of care, on the other hand, addresses the
entrustor’s right to receive quality service (in terms of
reasonable care and skill) from the fiduciary [27].Without needing to go to details, it is important to note
that the degree of strictness of the fiduciary duties varies
from one type of fiduciary to another and these variations
depend on the type of power entrusted to them, the avail-
ability of “monitoring and controls” that entrustors have
over the fiduciaries, the cost of using these monitors and
controls over the fiduciaries, the gravity of the risk with
which entrustors are exposed to due to the imposition of
power to the fiduciary, and the lack of alternatives to pro-
tect entrustors from these risks [27].
Physician-patient relationship as fiduciary relationship
That physicians are fiduciaries to their patients is best
expressed in cases such as Norberg v. Wynrib. In the lat-
ter case, for example, the Canadian Supreme Court un-
equivocally characterized physician-patient relationship
as fundamentally fiduciary in nature [30]. As fiduciaries,
without discounting the patients’ right and capacity for
self-determination, physicians have duties of loyalty and
care towards their patients. In terms of the duty of loy-
alty, the demands of which we have outlined above, in
compliance with their duty to account for “entrusted as-
sets”, physicians are required to protect the patient’s
privacy by for example safeguarding the patient’s infor-
mation. They should also not directly market and sell
drugs to their patients, as this puts their interest in dir-
ect conflict with that of their patients’. Engaging in “in-
appropriate sexual relationship or committing sexual
misconduct” [31] is another example where physicians
breach their duty of not letting their personal interest
conflict with their patients’ [32]. The breach of the duty
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power vested on the physician. We shall see in a short
while that though engaging in research also qualify as a
conflict of interest, there are procedures that allow for
the waiving of the duty to not engage in activities that
conflict with the patients’ best interest.
The duty of care, on the other hand, refers to the duty of
physicians to “exercise reasonable care, diligence and skill
in the exercise of their discretionary power (e.g., clinical
judgment in the diagnosis and treatment of a patient)” [32].
This may refer, for example, to physicians following GCP
protocols, requesting the necessary diagnostic tests before
providing a diagnosis, engaging the patient in the treatment
through shared decision making and personalized care,
providing balanced treatment options and recommenda-
tions based on the patient’s individualized condition, pro-
viding treatment follow-ups, among others.
Possibilities of waiver of some of the fiduciary obligations
for purposes of research
In some instances, fiduciary duties may be considered as
default rules, i.e., rules that “apply unless otherwise agreed”
[33]. Default rules may be waived through some sort of
agreement and procedure.
According to Frankel, most fiduciary obligations are
default obligations [34]. As such, it is possible for some
fiduciary obligations not only to be waived, but also to
be replaced by a contract, i.e., fiduciaries may propose to
their beneficiaries that some of their responsibilities be
waived and contracted. However, due to the dependence
of entrustors on beneficiaries, waiving may only be pos-
sible if the following procedures are followed:
Fiduciaries must put entrustors on notice that,
regarding the specified transaction, entrustors are on
their own; entrustors must have legal capacity to enter
into bargains with their fiduciaries as independent
parties; to enable entrustors to make informed
decisions, fiduciaries must provide them with
information regarding the transaction… [27].
The above-mentioned procedure is exactly the principle
behind informed consent in research: patients are in-
formed, and hence put on notice, that once they sign the
form, certain obligations of the physicians are waived or
compromised due to research; in the process of obtaining
informed consent, the patient’s capacity to consent must
be ascertained; lastly, in informing the patient about the re-
search, information sheets (or other similar materials) are
provided and explained to make sure that all the necessary
research procedures and repercussions are explained.
In the literature, there are discussions whether the
physician-researcher has fiduciary obligations to patient-
participants [35-37]. We think the literature has contributedgreatly in expounding on the negative and positive obliga-
tions of researchers towards research participants. However,
based on the foregoing discussion, we think it is unnecessary
to labor whether the physician, as a researcher, has a fidu-
ciary obligation towards the patient-participant. It makes
much more sense to view the physician-researcher as some-
one whose primary fiduciary obligation is to take care of the
well-being of the patient, but in instances of research, she/he
waives some of these obligations through the informed con-
sent procedure.
In research, some obligations are waived such as the
obligation towards personalized care, or the obligation
of loyalty not to conflict with the patient’s best interest.
The patient-participant will be placed in a situation
where treatment will be based on the protocol and not
only on the evaluation of the patient’s individualized
condition. However, as a natural fiduciary, the physician-
researcher retains her/his unwaived obligations such as
the obligation to deliberate on the patient’s situation,
and hence, decide whether it is still reasonable for the
patient to be part of the trial or whether, for the patient’s
interest, the patient ought to be removed from the trial.
Or, in the event that the physician-researcher is involved
in the design of the trial, she/he must “put the protec-
tion of the participants’ interests first” [26] by making
sure that proper safety procedures are present and that
risks are acceptable to and for the patient-participants.
Indeed, Helsinki article 9 lists the physicians’ (fiduciary)
duties that are retained in a trial:
It is the duty of physicians who are involved in
medical research to protect the life, health, dignity,
integrity, right to self-determination, privacy, and con-
fidentiality of personal information of research sub-
jects. The responsibility for the protection of research
subjects must always rest with the physician or other
health care professionals and never with the research
subjects, even though they have given consent [24].
Hence, not all fiduciary duties are default duties. Frankel
mentions three instances when fiduciary obligations are
“mandatory”: when leveling the playing field for fiduciar-
ies; when protecting the fundamental tenets of society;
and when providing paternalistic protections [34]. For our
purposes, we shall call these generic mandatory fiduciary
obligations. By generic, we mean that these obligations
apply to all physician-researchers who are involved in any
clinical trial. It will be best to briefly illustrate how some
of the restrictions in ethics guidelines that are very much
familiar to us may be rooted or contextualized within
these generic mandatory fiduciary obligations.
Leveling the playing field The retained obligations in
Helsinki article 9 as we saw above provide for a level
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ensure that the quality of services is not “less-than-
acceptable” [34] in all clinical trials. The field is not only
more or less level for patient-participants but for the
physician-researchers as fiduciaries as well.
Protecting society’s fundamental tenets A physician
may also not engage her/himself in a research with un-
acceptably high risks or with research that is methodo-
logically faulty because researches such as these go
against the fundamental tenet of society of protecting its
citizens against undue harm. As somewhat an articula-
tion of a prohibition on physicians from involving them-
selves in trials with unacceptable risk, Helsinki article 18
states the following: “Physicians may not be involved in
a research study involving human subjects unless they
are confident that the risks have been adequately
assessed and can be satisfactorily managed” [24]. In the
same manner, Helsinki article 21 also stipulates that a
trial must in all instances be scientifically sound; as such,
physicians may not engage themselves in researches that
are methodologically faulty or are only scantly scientific
but are cover-ups for other purposes such as marketing
and promotion.
Providing paternalistic protections In instances of
patient-participant incompetence, paternalistic protec-
tions require physician-researchers, for example, to
deal with both the patient-participant and her/his le-
gally authorized representative and to clearly explain to
them which aspects of “care are related to the research”
(Helsinki article 31).
With these points clarified, we can now return to our
main context, i.e., phase IV.
The physician-researcher within the context of phase IV
We earlier saw that phase IV trials are intimately linked
with practice such that the therapeutic expectation of
the patient-participant is not something that needs vig-
orous dispelling: with the exception of placebo arms,
safety and effectiveness ought to be reasonably expected;
in addition, this therapeutic expectation from patient-
participants, and maybe even of the physician-researchers,
is part of real life, the setting from which phase IV trials
aim to gather evidence from to eventually inform clinical
decisions. With this in mind, and given our earlier discus-
sions of the guidelines and fiduciary obligation, we can with
confidence say that within the context of post-authorization
trials, physician-researchers put the interest of the patient-
participants first by being fiduciaries who retain their
therapeutic obligation to their patient-participants. Hence,
in this phase, on top of the generic mandatory obligations
of physician-researchers as fiduciaries we discussed above,
the fiduciary obligation of the physician to treat (i.e., her/his therapeutic obligation) is not easily waived as in other
phasesb.
If the fiduciary obligation to treat of the physician-
researcher is not as easily waived in phase IV, this would
have concrete repercussions on the design, methodology,
and manner of conducting such trials. This therapeutic
obligation would for example affect the use of placebo
and of noninferiority trial design in this phase. Before
we spell out what some of these repercussions may be,
we need a caveat: even though the end-provider of this
therapeutic obligation in phase IV is the physician-
researcher, the responsibility of safeguarding the thera-
peutic aspect of phase IV cannot lie on the physician
alone. Physician-researchers, investigators, and research
ethics committees should all allow for this environment
where this therapeutic obligation of the physician is up-
held. Concretely, this may mean their cooperation to ful-
fill the following:
1.) as much as possible, placebo is not usedc;
2.) nonblinded studies are preferred over blinded ones
to allow the physician-researcher to discuss the ram-
ifications, effects, and side-effects of the drug to the
patient-participantd;
3.) superiority trials are preferred over noninferiority
trials due to the clinical value of the previous over
the lattere;
4.) trial methodology and design should consider the
therapeutic value of the trial to the patient-participant;
5.) as much as reasonably possible, with the exception
of the trial drug, the physician-researcher should
be allowed to prescribe other drugs and request
necessary diagnostic tests for therapy purposes.
The deviation from any of these points should be rea-
sonably defended by the study sponsor to the ethics
committee, and the ethics committee should find sub-
stantive justification for the said deviation.
Conclusion
Physicians are the fiduciaries of patients and as such,
they ought to put the interest of the patient first. In
some instances, the waiving of some of the obligations
of the physicians to the patients is possible, as in the
case of research. However, fiduciary obligations are not
always default obligations. In phase IV where research
is more intimately related to practice, the physician-
researcher ought to lean more towards practice than to
research. Hence, in this phase, Concretely, this means
that physician-researchers (in collaboration with other
researchers, investigators, and research ethics commit-
tees) should ensure that in terms of study design, meth-
odology, and research practice, the therapeutic value of
the research to the patient-participants is not diminished.
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aWe are in no way claiming that phase IV trials are ab-
solutely of lower risk than earlier trials for the following
reasons. When we speak of phase IV interventional
studies, two aspects come directly into mind: 1.) the na-
ture and purpose of the study; 2.) the registered indica-
tion for the drug. Starting with 2, the risk should be
relatively lower in phase IV studies because the informa-
tion obtained in the regulatory program has been built
in, at least compared to that in phases II and III. Having
said that, in the early phases, a stricter set of inclusion
criteria will be followed, thus avoiding a potential prob-
lem with co-morbidities and substantial age differences,
for instance. Once a study in phase IV is set up to have
data on a broader patient population, certain unforeseen
more rare risks may increase but the overall risks cannot
be expected to be higher, since the most frequent, plaus-
ible and scientifically to be expected (e.g., involvement
of interactions based on the use of common pathways
for degradation) are known or have been excluded by
the outcome of earlier studies. Hence, it is not so much
the quantity but the qualitative aspects of adverse events
that are of importance and hence, we would therefore
not support to offer less protection. Adding to that is
off-label use and although one could say that the manu-
facturer cannot control such use, problems for the pa-
tients can also arise. A large interventional study has the
potential to offer additional information on broader use
because it reflects proper, less proper, and wrong pre-
scribing habits, where we again cannot with confidence
say that protection should be less than those in earlier
trials. As such, due to these various considerations, we
cannot say that phase IV interventional trials indeed
have lower risks than earlier phases and hence need less
protection.
bThere may be concerns that in earlier trials, especially
in phase III, medical doctors may also be willing to en-
roll a patient in a potentially therapeutic trial because
the doctor is in equipoise as to which therapy is best,
and thus, the difference in terms of fiduciary obligations
waived may not be significant. We argue that in phase
III, the fiduciary obligation of the physician to choose
based on what is best for the patient will have to be
compromised, even if theoretically, the scientific-medical
community is in equipoise. In phase III, there are gener-
ally more research-interventions (such as extra blood
draws or other diagnostic procedures) than in most
phase IV studies, and this is a further compromise of the
fiduciary obligation of the physician. Placebo is also
more common in phase III. In contrast, in this section,
we argue that because of the therapeutic orientation of
phase IV, and hence the fiduciary obligation of the phys-
ician is less compromised, placebo as much as possible
should not be used, that nonblinded studies are preferredover blinded ones, that as much as possible, physicians
should be allowed to prescribe other drugs and request
necessary diagnostic tests, etcetera. As such, we believe
we are justified in stating that less aspects of the fiduciary
obligation is waived in phase IV.
cLast 17 May 2013, we searched www.clinicaltrials.gov
for clinical trials using the following restrictions: pla-
cebo, interventional, and phase 4. In total, there were
3941 studies.
dLast 17 May 2013, we searched www.clinicaltrials.gov
for clinical trials using the following restrictions: blinded
interventional, phase IV. In total, there were 588 studies.
eLast 17 May 2013, we searched www.clinicaltrials.gov
for clinical trials with the following restrictions: noninfe-
riority, interventional, phase IV. In total, there were 130
studies.
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